why Takeda Pharmaceutical Company Limited [TAK] is a Good Choice for Investors After New Price Target of $17.87


Takeda Pharmaceutical Company Limited [NYSE: TAK] stock went on a downward path that fall over -0.80% on Thursday, amounting to a one-week price decrease of less than -0.95%. The company report on December 21, 2021 that Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.1.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in its present form. In addition, the FDA recommended an additional clinical study in order to help resolve FDA feedback.

Over the last 12 months, TAK stock dropped by -25.30%. The one-year Takeda Pharmaceutical Company Limited stock forecast points to a potential upside of 24.01. The average equity rating for TAK stock is currently 2.30, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $42.81 billion, with 3.14 billion shares outstanding and 3.12 billion shares in the current float. Compared to the average trading volume of 2.72M shares, TAK stock reached a trading volume of 2063213 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Takeda Pharmaceutical Company Limited [TAK]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TAK shares is $17.87 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TAK stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Takeda Pharmaceutical Company Limited shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on October 07, 2021. The new note on the price target was released on April 19, 2021, representing the official price target for Takeda Pharmaceutical Company Limited stock. Previously, the target price had yet another raise to $19.50, while Cowen analysts kept a Market Perform rating on TAK stock.

The Average True Range (ATR) for Takeda Pharmaceutical Company Limited is set at 0.17, with the Price to Sales ratio for TAK stock in the period of the last 12 months amounting to 1.44. The Price to Book ratio for the last quarter was 0.92, with the Price to Cash per share for the same quarter was set at 1.76. Price to Free Cash Flow for TAK in the course of the last twelve months was 7.95 with Quick ratio for the last quarter at 0.90.

TAK Stock Performance Analysis:

Takeda Pharmaceutical Company Limited [TAK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.95. With this latest performance, TAK shares gained by 1.72% in over the last four-week period, additionally sinking by -19.64% over the last 6 months – not to mention a drop of -25.30% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TAK stock in for the last two-week period is set at 43.26, with the RSI for the last a single of trading hit 42.54, and the three-weeks RSI is set at 42.30 for Takeda Pharmaceutical Company Limited [TAK]. The present Moving Average for the last 50 days of trading for this stock 13.88, while it was recorded at 13.67 for the last single week of trading, and 16.11 for the last 200 days.

Insight into Takeda Pharmaceutical Company Limited Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Takeda Pharmaceutical Company Limited [TAK] shares currently have an operating margin of +14.00 and a Gross Margin at +56.24. Takeda Pharmaceutical Company Limited’s Net Margin is presently recorded at +11.76.

Return on Total Capital for TAK is now 4.38, given the latest momentum, and Return on Invested Capital for the company is 3.81. Return on Equity for this stock inclined to 7.60, with Return on Assets sitting at 2.92. When it comes to the capital structure of this company, Takeda Pharmaceutical Company Limited [TAK] has a Total Debt to Total Equity ratio set at 98.12. Additionally, TAK Total Debt to Total Capital is recorded at 49.53, with Total Debt to Total Assets ending up at 39.28. Long-Term Debt to Equity for the company is recorded at 96.72, with the Long-Term Debt to Total Capital now at 48.82.

Reflecting on the efficiency of the workforce at the company, Takeda Pharmaceutical Company Limited [TAK] managed to generate an average of $7,983,291 per employee. Receivables Turnover for the company is 4.00 with a Total Asset Turnover recorded at a value of 0.25.Takeda Pharmaceutical Company Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.30.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TAK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Takeda Pharmaceutical Company Limited go to 0.58%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Takeda Pharmaceutical Company Limited [TAK] Insider Position Details

There are presently around $1,271 million, or 3.00% of TAK stock, in the hands of institutional investors. The top three institutional holders of TAK stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 13,501,650, which is approximately -12.853% of the company’s market cap and around 0.01% of the total institutional ownership; GLENVIEW CAPITAL MANAGEMENT, LLC, holding 8,102,119 shares of the stock with an approximate value of $110.92 million in TAK stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $75.55 million in TAK stock with ownership of nearly 2.462% of the company’s market capitalization.

Positions in Takeda Pharmaceutical Company Limited stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 114 institutional holders increased their position in Takeda Pharmaceutical Company Limited [NYSE:TAK] by around 8,263,729 shares. Additionally, 128 investors decreased positions by around 11,466,167 shares, while 78 investors held positions by with 73,104,635 shares. The mentioned changes placed institutional holdings at 92,834,531 shares, according to the latest SEC report filing. TAK stock had 30 new institutional investments in for a total of 504,907 shares, while 37 institutional investors sold positions of 2,697,086 shares during the same period.